Charles Dunn

Charles joined SV Health Investors in 2018 and is a Vice President in the Biotech team. His role spans from formation to funding of companies that develop transformational new medicines, with a broad focus from new company creation to later stage public and private opportunities.

In addition to Imbria, Charles serves on the Board of Mestag Therapeutics, which he incubated and launched. Charles is also Board Observer at Autifony Therapeutics, EnaraBio and Pulmocide. Prior to joining SV Health, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences’ clients including SV Health portfolio companies. Charles holds a MSci Human Genetics, University College London (UCL) and is a chartered accountant (ACA).